Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment

单克隆抗体 医学 药品 抗体-药物偶联物 乳腺癌 结合 抗体 癌症 癌症研究 免疫学 药理学 内科学 数学分析 数学
作者
Swati Saini,Nisha Gulati,Rajendra Awasthi,Vimal Arora,Sachin Kumar Singh,Shobhit Kumar,Gaurav Gupta,Kamal Dua,Rakesh Pahwa,Harish Dureja
出处
期刊:Current Drug Delivery [Bentham Science]
卷期号:21 (7): 993-1009 被引量:11
标识
DOI:10.2174/1567201820666230731094258
摘要

When breast cells divide and multiply out of control, it is called breast cancer. Symptoms include lump formation in the breast, a change in the texture or color of the breast, or a discharge from the nipple. Local or systemic therapy is frequently used to treat breast cancer. Surgical and radiation procedures limited to the affected area are examples of local management. There has been significant worldwide progress in the development of monoclonal antibodies (mAbs) since 1986, when the first therapeutic mAb, Orthoclone OKT3, became commercially available. mAbs can resist the expansion of cancer cells by inducing the destruction of cellular membranes, blocking immune system inhibitors, and preventing the formation of new blood vessels. mAbs can also target growth factor receptors. Understanding the molecular pathways involved in tumor growth and its microenvironment is crucial for developing effective targeted cancer therapeutics. Due to their unique properties, mAbs have a wide range of clinical applications. Antibody-drug conjugates (ADCs) are drugs that improve the therapeutic index by combining an antigen-specific antibody with a payload. This review focuses on the therapeutic applications, mechanistic insights, characteristics, safety aspects, and adverse events of mAbs like trastuzumab, bevacizumab, pertuzumab, ertumaxomab, and atezolizumab in breast cancer treatment. The creation of novel technologies utilizing modified antibodies, such as fragments, conjugates, and multi-specific antibodies, must be a central focus of future studies. This review will help scientists working on developing mAbs to treat cancers more effectively.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青应助跳跃的含双采纳,获得10
1秒前
英姑应助墨鱼烩饭采纳,获得10
1秒前
Hi完成签到,获得积分20
1秒前
慕课魔芋发布了新的文献求助10
1秒前
思源应助都是采纳,获得10
1秒前
艾绒完成签到,获得积分10
1秒前
1秒前
WM应助飞飞飞想要飞高高采纳,获得20
2秒前
祯果粒完成签到,获得积分10
2秒前
自觉断秋完成签到,获得积分10
2秒前
魏ye发布了新的文献求助10
3秒前
怕热除铁完成签到,获得积分10
3秒前
3秒前
lhh发布了新的文献求助10
4秒前
朴素元珊完成签到,获得积分10
4秒前
5秒前
6秒前
蛋蛋发布了新的文献求助10
6秒前
善学以致用应助感动初柔采纳,获得10
6秒前
宋祝福完成签到 ,获得积分10
7秒前
认真的蜜粉完成签到,获得积分10
8秒前
喜悦的飞机完成签到,获得积分10
8秒前
小蘑菇应助烟雨1采纳,获得10
9秒前
霖宸羽完成签到,获得积分10
9秒前
传奇3应助Wendy采纳,获得10
10秒前
Ava应助东风de夢采纳,获得10
10秒前
李健的小迷弟应助lily采纳,获得10
11秒前
魏ye完成签到,获得积分10
11秒前
wuhen发布了新的文献求助10
11秒前
Guoqiang发布了新的文献求助10
11秒前
12秒前
kk完成签到,获得积分20
12秒前
ding应助mmmmmmgm采纳,获得10
13秒前
脑洞疼应助九旁十五便士采纳,获得10
13秒前
14秒前
LHP完成签到,获得积分10
15秒前
rika发布了新的文献求助10
15秒前
共享精神应助认真的蜜粉采纳,获得10
15秒前
英姑应助阿航采纳,获得10
15秒前
16秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3083043
求助须知:如何正确求助?哪些是违规求助? 2736283
关于积分的说明 7540658
捐赠科研通 2385697
什么是DOI,文献DOI怎么找? 1265066
科研通“疑难数据库(出版商)”最低求助积分说明 612909
版权声明 597702